Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127192331 | 12719233 | 1 | I | 20160825 | 20160907 | 20160907 | EXP | CN-TAKEDA-2016MPI007713 | TAKEDA | LU J, HOU J, ZHANG C, YUAN Z, LAN H, ZHOU F, ET AL.. THE EFFICACY AND SAFETY ANALYSIS OF BORTEZOMIB RETREATMENT IN 76 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.. CHIN J HEMATOL. 2013;34(4):309-312 | 0.00 | Y | 0.00000 | 20160906 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127192331 | 12719233 | 1 | PS | VELCADE | BORTEZOMIB | 1 | Intravenous (not otherwise specified) | 1 MG/M2, UNK | U | 21602 | 1 | MG/M**2 | INJECTION | ||||||
| 127192331 | 12719233 | 2 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Unknown | UNK | U | 0 | |||||||||
| 127192331 | 12719233 | 3 | SS | EPIRUBICIN | EPIRUBICIN | 1 | Unknown | UNK | U | 0 | |||||||||
| 127192331 | 12719233 | 4 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | UNK | U | 0 | |||||||||
| 127192331 | 12719233 | 5 | SS | MELPHALAN | MELPHALAN | 1 | Unknown | UNK | U | 0 | |||||||||
| 127192331 | 12719233 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | UNK | U | 0 | |||||||||
| 127192331 | 12719233 | 7 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127192331 | 12719233 | 1 | Plasma cell myeloma |
| 127192331 | 12719233 | 2 | Plasma cell myeloma |
| 127192331 | 12719233 | 3 | Plasma cell myeloma |
| 127192331 | 12719233 | 4 | Plasma cell myeloma |
| 127192331 | 12719233 | 5 | Plasma cell myeloma |
| 127192331 | 12719233 | 6 | Plasma cell myeloma |
| 127192331 | 12719233 | 7 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127192331 | 12719233 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127192331 | 12719233 | Cardiovascular disorder | |
| 127192331 | 12719233 | Diarrhoea | |
| 127192331 | 12719233 | Fatigue | |
| 127192331 | 12719233 | Neuropathy peripheral | |
| 127192331 | 12719233 | Neutropenia | |
| 127192331 | 12719233 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |